摘要
目的:建立阿昔洛韦2/3水合物的制备方法和完整的晶型表征分析方法。方法:在水中重结晶制备阿昔洛韦2/3水合物,并采用衰减全反射红外和红外吸收光谱、差示扫描量热分析、热重分析、粉末和单晶X-射线衍射法对该晶型进行全面的表征。结果:获得了阿昔洛韦2/3水合物晶型制备和表征方法,得到了傅立叶衰减全反射红外光谱和热重分析谱图,通过热分析法探明了阿昔洛韦2/3水合物向无水晶型转化和无水晶型间转化的过程及其对应的热效应,5.18%的失重率对应于2/3结晶水。结论:所建立的晶型制备方法简便,阿昔洛韦2/3水合物晶型表征方法可靠,数据全面。
Objective: To establish the methods for preparation and characterization of acyclovir 2/3 hydrate. Meth- ods : Acyclovir 2/3 hydrate was obtained by re - crystallization using water as the solvent and was comprehensively characterized by infrared spectroscopy, differential scanning calorimetry ( DSC ), thermogravimetry analysis ( TGA ), and X - ray diffraction. Results: The preparation and characterization method for the crystal form of acyclovir 2/3 hydrate was achieved. The attenuated total reflectance fourier transform infrared spectrum( ATR -FT -IR) and the TGA spectrum were reported for the first time. In thermal analysis, the thermal events of transformation from hydrate to anhydrous form were demonstrated and the weight loss of 5.18% observed in the TGA curve was equivalent to the stoichiometric water content in aeyclovir 2/3 hydrate. Conclusion: The established crystal preparation method is simple, and the characterization method for the acyclovir 2/3 hydrate crystal is reliable with sufficient data.
出处
《药物分析杂志》
CAS
CSCD
北大核心
2013年第9期1636-1639,共4页
Chinese Journal of Pharmaceutical Analysis
基金
浙江省应对技术性贸易壁垒技术攻关项目(2010357)
浙江省新产品计划项目(2008D60SA870353)
关键词
多晶型药物
阿昔洛韦2
3水合物
衰减全反射红外光谱
红外吸收光谱
差示扫描量热分析
热重分析
X-射线衍射
polymorphic drug
acyclovir 2/3 hydrate
attenuated total reflection infrared spectroscopy
infrared spec- troscopy
differential scanning calorimetry
thermogravimetry analysis
X - ray diffractometry